Myogen to Announce 2006 Second Quarter Results on August 7, 2006

Myogen, Inc. (Nasdaq:MYOG), a biopharmaceutical company
focused on the discovery, development and commercialization of small
molecule therapeutics for the treatment of cardiovascular disorders,
today announced that it will report 2006 second quarter results the
afternoon of Monday, August 7, 2006.
   J. William Freytag, President and CEO, and other members of
Myogen's senior management will provide a company update and discuss
results via webcast and conference call on Monday, August 7, 2006, at
4:30 p.m. Eastern time. To access the live webcast, please log on to
the company's website at www.myogen.com and go to the Investor
Relations section. Alternatively, callers may participate in the
conference call by dialing 800-218-0713 (domestic) or 303-262-2140
(international). Webcast and telephone replays of the conference call
will be available approximately two hours after the completion of the
call through Friday, August 18, 2006. Callers can access the replay by
dialing 800-405-2236 (domestic) or 303-590-3000 (international). The
passcode is 11065905.

   About Myogen

   Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension (PAH) and darusentan for the treatment of
patients with resistant hypertension. Myogen and GlaxoSmithKline have
entered into a global PAH collaboration in which Myogen has marketing
and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol
sodium) for Injection in the United States and GlaxoSmithKline has
licensed ambrisentan from Myogen for all territories outside of the
United States, where Myogen retains exclusive rights. Myogen also
conducts a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com.

   Safe Harbor Statement

   The 2006 second quarter results press release and conference call
will contain forward-looking statements that involve significant risks
and uncertainties, including those that can be found in the "Risk
Factors" section of Myogen's Form 10-K for the year ended December 31,
2005, and in Myogen's periodic reports on Form 10-Q and Form 8-K.
Myogen is providing the information contained in the release and
conference call as of the date of the release and does not undertake
any obligation to update any forward-looking statements as a result of
new information, future events or otherwise. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.